Pairwise comparison of targeted pharmacogenomic and comprehensive cancer panel sequencing-based mutation profiles between 5FU-resistant and matched parental cell lines identified a missense mutation in neurofibromatosis type 1 (NF1), c.5461G>T (V1821F) that is unique to the 45FU cell line (Fig. 3, B and C). This evidence concerns the gene NF1 and cancer.